uniQureQURE
QURE
About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Employees: 209
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
292% more call options, than puts
Call options by funds: $51.5M | Put options by funds: $13.2M
281% more capital invested
Capital invested by funds: $193M [Q3] → $734M (+$541M) [Q4]
33% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 27
5.53% more ownership
Funds ownership: 79.83% [Q3] → 85.36% (+5.53%) [Q4]
5% more funds holding
Funds holding: 130 [Q3] → 137 (+7) [Q4]
23% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 47
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
103%
upside
Avg. target
$46
212%
upside
High target
$70
374%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 22% 1-year accuracy 42 / 187 met price target | 374%upside $70 | Buy Reiterated | 21 Apr 2025 |
Chardan Capital Daniil Gataulin 22% 1-year accuracy 11 / 50 met price target | 157%upside $38 | Buy Maintained | 1 Apr 2025 |
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target | 103%upside $30 | Equal-Weight Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 5 articles about QURE published over the past 30 days
Positive
Zacks Investment Research
1 week ago
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Seeking Alpha
1 week ago
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth.
Neutral
Seeking Alpha
1 week ago
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operations through H2 2027, reducing immediate financial risk. AMT-191 for Fabry Disease and AMT-162 for ALS are also advancing, diversifying uniQure's pipeline and potential market impact.
Positive
Benzinga
1 week ago
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to uniQure N.V.'s QURE AMT-130 for Huntington's disease on Thursday
Neutral
GlobeNewsWire
1 week ago
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~
Negative
Zacks Investment Research
2 months ago
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
UniQure (QURE) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.53 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~
Positive
Seeking Alpha
2 months ago
uniQure N.V.: A Potential Huntington's Play
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share.
Positive
Seeking Alpha
2 months ago
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025.
Positive
Benzinga
2 months ago
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients.
Charts implemented using Lightweight Charts™